VOLUME 46 / SUPPLEMENT 59 / SEPTEMBER 2015

EUROPEAN RESPIRATORY *journal*

OFFICIAL SCIENTIFIC JOURNAL OF THE ERS

Abstracts / 25th International Congress Amsterdam, Netherlands 26 – 30 September 2015



Copyright for individual abstracts remains with the authors.

This abstract supplement has been produced electronically by the European Respiratory Society. The European Respiratory Society is not responsible for errors or omissions in content. The ideas and opinions expressed in this publication do not necessarily reflect those of Coe-Truman and the European Respiratory Society. Products mentioned in this publication should not be construed as an endorsement of the product or the manufacturer's claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The European Respiratory Society assumes no responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material contained in these abstracts. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. An effort has been made to check generic and trade names, and to verify drug doses. The ultimate responsibility, however, lies with the prescribing physician. Please convey any errors to scientific@ersnet.org.

Citations should be made in the following way: Authors. Title. Eur Respir J 20015; 46: Suppl. 59, abstract number.



Table Of Content

411. Inflammation and remodelling in lung disease	2
PA3915: Prooxidant-antioxidant balance in mustard airway disease with different severity	2
PA3925: Serum metabolomic analysis of mustard airway diseases by nuclear magnetic resonance spectrometry: A pilot study	2



411. Inflammation and remodelling in lung disease

PA3915

Prooxidant-antioxidant balance in mustard airway disease with different severity

Daryoush Hamidi Alamdari¹, B. Fatemeh Nobakht M. Gh.², Afsaneh Arefi Oskouie³, Mostafa Rezaei-Tavirani², Alireza Akbarzadeh Baghban⁴, <u>Rasoul</u> <u>Aliannejad⁵</u>

⁵Stem Cell and Regenerative Medicine Research Group, Department of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran; ³Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran; ³Department of Basic Sciences, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran; ¹Department of Basic Sciences, Tehran, Islamic Republic of Iran; ¹Department of Basic Sciences, School of Rehabilitation,Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran; ¹Department of Pulmonary, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran

Introduction: Sulfur mustard (SM) is a strong alkylating agent that primarily targets the skin, eye, and lung. Mustard airway is a major late complication of SM exposure. Aims and objectives: Current study evaluated long-term effect of SM on oxidizing and reducing agents values using new method prooxidantantioxidant balance (PAB) assay in human plasma of SM-injured patients. Methods: sera of 35 SM-exposed patients and 19 healthy controls were recruited. Both groups had nonsmoker and nonalcoholic people with no diseases. The PAB was measured by a new method, recently developed by hamidi, by using 3,3',5,5'-Tetramethylbenzidine (TMB) and two different kinds of reactions; one enzymatic reaction and a chemical reaction that noted prooxidant- antioxidant balance (PAB) assay. Results: Mean PAB values in control group were 48.74±21.07 HK (Hamidi and Koliakos), PAB levels were 101.45±32.68 HK in SM-exposed patients with normal pulmonary function test and 120.23±31.55 HK in severe obstruction pulmonary disease. . Conclusions: the level of oxidation is not related to the severity of disease defined by spirometry findings and a significant negative correlation was established between the PAB value and FEV1. The increased PAB value in chemical casualties showed that these patients are exposed to oxidative stress.Likely, at first cytotoxic levels of SM can directly induce oxidative stress (OS), but many years after exposure the levels of OS were elevated through indirectly effects of inflammatory process.

PA3925

Serum metabolomic analysis of mustard airway diseases by nuclear magnetic resonance spectrometry: A pilot study

B. Fatemeh Nobakht M. Gh.¹, <u>Rasoul Aliannejad²</u>, Salman Taheri³, Mostafa Rezaei-Tavirani¹, Fariba Fathi⁴, Afsaneh Arefi Oskouie⁵

¹Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran; ²Department of Pulmonary, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran; ³Chemistry and Chemical Engineering Research Center of Iran, Tehran, Islamic Republic of Iran; ⁴Department of Chemistry, Sharif University of Technology, Tehran, Islamic Republic of Iran; ⁵Department of Basic Sciences, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran

Introduction: Nuclear magnetic resonance (NMR) spectroscopy is an ideal platform for the metabolic analysis of biofluids. Sulfur mustard (SM) is a alkylating chemical warfare agent that cause lung injury and despite years of research there is no common consensus about the pathophysiological basis of mustard airway disease. Aims and objectives: we used ¹H NMR spectroscopy to explore the metabolic profile of sera from mustard airway disease patients. Methods: A total of twenty nine serum samples obtained from SM-injured patients (n=17) and healthy controls (n=12) were investigated. Random forest (RF) analysis was capable of distinguishing SM-exposed patients from controls. Results: A total of 18 metabolites differed significantly in intensity between the two groups. Serum samples from SM-injured patients were characterized by increased concentrations of amino acid metabolism (Lglutamine, L-glutamate, L-asparagine, L-lysine, L-glycine, L-proline, and 4-hydroxyproline), lipid metabolism, citrate, ketone bodies, organic acid (lactate and acetate), urea pathway (citrulline), and creatine, relative to control subjects. Discussion: Our study reveals the metabolic profile of sera from SMinjured patients and indicates that NMR-based methods can distinguish these patients from healthy controls. .Also, serum Metabolomic profile of COPD patients differ with mustard airway disease by increased levels of methylhistidine (a muscle protein) and reduced levels of branched-chain amino

acids as well as 4-hydroxyproline and proline. It suggests that Metabolomicbased diagnostics not only can distinguish mustard airway disease with healthy controls, but also can diagnose from COPD.